Hyderabad-based Dr Reddy’s Laboratories has launched the prescription drug Minoxidil topical solution  USP  2 per cent and 5 per cent for the treatment of female pattern hair loss (FPHL). Dr Reddy’s will sell its products under the brand names Mintop 2 per cent and Mintop Eva 5 per cent respectively.
 
The launch follows the first-ever approval of the additional indication by the Central Drugs Standard Control Organization (CDSCO)  in  India for the use of  Minoxidil topical solution USP 2 per cent and 5 per cent for treatment of FPHL.

Minoxidil topical solution will become available as a first-line treatment option for FPHL in India. While Minoxidil topical solution has been approved in India for the treatment of alopecia in men (male pattern baldness), there are presently no other drugs approved for the treatment of FPHL in India.

MV Ramana, CEO, Branded Markets (India & Emerging Markets) Dr Reddy’s Laboratories said, “This approval marks the first-ever given to a first-line treatment option for female pattern hair loss, and truly fulfils a hitherto unmet need. Our Minoxidil topical solution (Mintop 2 per cent and Mintop Eva 5 per cent) for women will be widely available in the country, and through this launch, we hope to bring relief and comfort to patients diagnosed with FPHL in India.”